- SalvaRx Group Plc is a Isle of Man-based company. The Company engaged in drug discovery and development, focused on immune oncology. The Company invests in novel cancer immuno-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies.

Employees

Sector

Biotechnology & Medical Research

More about the company

26/09/19	SalvaRx Evaluates Takeover Opportunities	CI
26/09/19	Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	CI

Market Cap	1.65M 1.42M 1.33M 1.22M 2.28M 156M 2.3M 15.77M 6.14M 79.78M 6.2M 6.07M 257M	P/E 2017	-4.13x	P/E 2018	83x
Enterprise Value	2.41M 2.08M 1.95M 1.78M 3.33M 228M 3.36M 23.06M 8.98M 117M 9.07M 8.87M 376M	EV / Sales 2017	-	EV / Sales 2018	-
Free-Float	20.33%	Yield 2017 *	-	Yield 2018	-

26/09/19	SalvaRx Evaluates Takeover Opportunities	CI
26/09/19	Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	CI
28/06/19	Salvarx Group plc Reports Earnings Results for the Full Year Ended December 31, 2018	CI
08/01/19	Portage Biotech Inc. (OTCPK:PTGE.F) completed the acquisition of SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile.	CI
27/09/18	SalvaRx Group plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	CI
14/08/18	Portage Biotech Inc. (OTCPK:PTGE.F) (‘Portage’) entered into a conditional sale agreement to acquire SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile for $80.5 million.	CI
28/06/18	SalvaRx Group plc Announces Consolidated Earnings Results for the Year Ended December 31, 2017	CI
28/06/18	SalvaRx Seeks Acquisitions	CI
26/06/18	SalvaRx Announces an Unsecured $1 Million Loan	CI
27/09/17	SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017	CI
30/06/17	SalvaRx Group plc Announces Final Audited Consolidated Earnings Results for the Year Ended December 31, 2016	CI
30/06/17	SalvaRx Seeks Investments	CI
30/05/17	SalvaRx Group plc Treats First Patient INT230-6 as Part of A Phase 1/2 International Clinical Study	CI

14/10/20	SalvaRx : Portage Issues Common Shares and Warrants in Settlement of SalvaRx Loan Note Obligations	AQ
27/09/19	SalvaRx : Half Yearly Report 30 June 2019 RNS	PU
26/09/19	SalvaRx : RNS SalvaRx Group PLC interim report 30 June 2019	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-1.79%	-3.82%	+38.74%	+91.90%	69.02B
ARGENX SE	-2.06%	-0.18%	+41.53%	+88.17%	66.32B
INSMED INCORPORATED	+0.17%	+7.38%	-10.70%	+382.69%	27.66B
BIONTECH SE	+1.81%	+2.52%	+1.11%	-14.23%	25.84B
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.61%	+34.45%	+11.39%	26.54B
GENMAB A/S	-1.46%	+0.42%	+24.07%	-18.70%	20.4B
PHARMAESSENTIA CORPORATION	-2.96%	-16.03%	+213.13%	+375.00%	17.63B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-6.69%	-4.69%	+539.74%	15.15B
EXELIXIS, INC.	+0.09%	+8.60%	+58.19%	+165.51%	14.65B
Average	-1.19%	-0.66%	+43.98%	+180.16%	31.47B
Weighted average by Cap.	-1.38%	-0.45%	+39.21%	+139.62%

3Legs Resources plc Stock London S.E.

Stocks

IM00B52P5P72

Biotechnology & Medical Research

Valuation : 3Legs Resources plc

Latest news : 3Legs Resources plc

Press Releases : 3Legs Resources plc

Bio Therapeutic Drugs

Financials

Company Profile

	2017	2018
Net sales	-	-
Net income	-1.74M -1.5M -1.41M -1.29M -2.4M -165M -2.42M -16.66M -6.49M -84.25M -6.55M -6.41M -271M	342K 294K 276K 253K 472K 32.33M 475K 3.27M 1.27M 16.52M 1.28M 1.26M 53.21M
Net Debt	2.22M 1.91M 1.79M 1.64M 3.06M 210M 3.09M 21.22M 8.27M 107M 8.34M 8.16M 346M	763K 656K 616K 564K 1.05M 72.13M 1.06M 7.29M 2.84M 36.86M 2.87M 2.8M 119M

End-of-day quote London S.E.
- ^GBX	-